Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart risk under the microscope: new diabetes study in southeast asia

NCT ID NCT07532863

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study reviews medical records of 400 adults aged 40-70 who were recently diagnosed with type 2 diabetes in five Southeast Asian countries. Researchers will look at health data from before and after diagnosis to understand how heart disease risk is distributed. No new treatments are given; the goal is to gather information to improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better identify and manage heart disease risk early in people with new type 2 diabetes in Southeast Asia.
What could go wrong
This is an observational study that only looks back at existing records, so it cannot prove cause and effect. Results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with T2DM identified in south asian countries.

Ages

40 to 70 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged greater than equal to (≥) 40 and less than (\<) 70 years * Male or female * Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023 Exclusion Criteria: * If any exclusion criterion is met, the participant will be excluded from the study. * T1DM or gestational diabetes * Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM * Pregnant women * With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease * Died within 12 months after first diagnosis of T2DM * Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    6 sites in 4 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • National Heart Institute

    NOT_YET_RECRUITING

    Kuala Lumpur, 50400, Malaysia

  • Novo Nordisk Investigational Site

    RECRUITING

    Singapore, Singapore

  • Siloam Hospitals Lippo Village

    NOT_YET_RECRUITING

    Tangerang, Banten, 15810, Indonesia

  • Siloam Hospitals Surabaya

    ENROLLING_BY_INVITATION

    Surabaya, East Java, 60281, Indonesia

  • The Medical City Ortigas

    NOT_YET_RECRUITING

    Pasig, National Capital Region, 1800, Philippines

  • University Malaya Medical Centre

    ENROLLING_BY_INVITATION

    Lembah Pantai, Kuala Lumpur, 59100, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.